Alnylam Pharmaceuticals, Inc.
ALNYAlnylam Pharmaceuticals, Inc. is a biotechnology company focused on developing RNA interference (RNAi) therapeutics to treat genetic, cardio-metabolic, liver, and neurological diseases. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company pioneers the use of RNA interference technology to silence specific genes associated with various illnesses, aiming to address unmet medical needs.
Company News
Alnylam Pharmaceuticals, a biotech company focused on RNA interference (RNAi) therapies, has shown significant growth since its 2004 IPO. The company has multiple approved drugs for rare diseases and a promising pipeline of potential treatments across various medical conditions.
Alnylam Pharmaceuticals reported strong Q3 earnings, beating analyst expectations with a 149% year-over-year sales increase and raised fiscal 2025 sales guidance. The company showed promising results for its drug Amvuttra in treating transthyretin amyloid cardiomyopathy.
The article discusses how AI is transforming drug development, potentially reducing research cycles from 10-15 years to 3-6 years. BlackRock Health Sciences Term Trust offers an 8.8% dividend and trades at a 13% discount, with potential for growth as AI accelerates pharmaceutical research.
Novartis showcased new research data across its Cardiovascular, Renal, and Metabolic disease portfolio, presenting 33 abstracts at ASN Kidney Week and AHA Scientific Sessions, highlighting clinical trial results for treatments in kidney and heart conditions.
The First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange-traded fund that provides broad exposure to the healthcare-biotech sector. The ETF tracks the NYSE Arca Biotechnology Index and has a relatively high expense ratio of 0.56%. Its top holdings include Alnylam Pharmaceuticals, Corcept Therapeutics, and United Therapeut...
